AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

Search

GlaxoSmithKline PLC

Abrir

SetorSaúde

1,456 2.64

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1415.5

Máximo

1462.5

Indicadores-chave

By Trading Economics

Rendimento

559M

501M

Vendas

105M

8.1B

P/E

Médio do Setor

23.581

63.778

EPS

0.232

Rendimento de Dividendos

4.3

Margem de lucro

6.172

Funcionários

68,629

EBITDA

-52M

1.1B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+8.46% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.30%

2.39%

Próximos Ganhos

30 de abr. de 2025

Próxima data de dividendos

10 de abr. de 2025

Próxima data de ex-dividendo

15 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-586M

59B

Abertura anterior

1453.36

Fecho anterior

1456

Sentimento de Notícias

By Acuity

38%

62%

139 / 386 Ranking em Healthcare

GlaxoSmithKline PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de fev. de 2025, 11:32 UTC

Ganhos

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5 de fev. de 2025, 08:56 UTC

Ganhos

Correction to GSK Article

5 de fev. de 2025, 08:24 UTC

Ganhos

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5 de fev. de 2025, 07:43 UTC

Ganhos

GSK Expects Further Profit Growth After Beating Market Views

13 de jan. de 2025, 07:14 UTC

Aquisições, Fusões, Aquisições de Empresas

GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion

2 de abr. de 2025, 09:27 UTC

Ações em Alta

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 de mar. de 2025, 22:29 UTC

Principais Notícias

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26 de mar. de 2025, 19:19 UTC

Principais Notícias

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26 de mar. de 2025, 17:39 UTC

Principais Notícias

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19 de mar. de 2025, 14:50 UTC

Principais Notícias

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17 de mar. de 2025, 09:00 UTC

Principais Notícias

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24 de fev. de 2025, 07:05 UTC

Aquisições, Fusões, Aquisições de Empresas

GSK Completes Acquisition of IDRx

14 de fev. de 2025, 11:38 UTC

Principais Notícias
Ganhos

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14 de fev. de 2025, 11:30 UTC

Principais Notícias
Ganhos

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5 de fev. de 2025, 15:33 UTC

Conversa de Mercado
Ganhos

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5 de fev. de 2025, 08:38 UTC

Conversa de Mercado
Ganhos

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5 de fev. de 2025, 07:05 UTC

Ganhos

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5 de fev. de 2025, 07:04 UTC

Ganhos

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5 de fev. de 2025, 07:03 UTC

Ganhos

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5 de fev. de 2025, 07:03 UTC

Ganhos

GSK PLC Raises Mid-Term View

5 de fev. de 2025, 07:03 UTC

Ganhos

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5 de fev. de 2025, 07:02 UTC

Ganhos

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

5 de fev. de 2025, 07:02 UTC

Ganhos

GSK PLC Issues GBP2B Buyback

5 de fev. de 2025, 07:01 UTC

Ganhos

GSK PLC Declares 4Q Dividend of 16p

5 de fev. de 2025, 07:00 UTC

Ganhos

GSK PLC 4Q Core EPS Consensus Was 20.6p

5 de fev. de 2025, 07:00 UTC

Ganhos

GSK PLC 4Q Sales Consensus Was GBP7.83B

5 de fev. de 2025, 07:00 UTC

Ganhos

GSK PLC 4Q Pretax Pft GBP563M

5 de fev. de 2025, 07:00 UTC

Ganhos

GSK PLC 4Q EPS 10.0p

5 de fev. de 2025, 07:00 UTC

Ganhos

GSK PLC 4Q Adj EPS 23.2p

5 de fev. de 2025, 07:00 UTC

Ganhos

GSK PLC 4Q Oper Pft GBP696M

Comparação entre Pares

Variação de preço

GlaxoSmithKline PLC Previsão

Preço-alvo

By TipRanks

8.46% parte superior

Previsão para 12 meses

Média 1,593.33 GBX  8.46%

Máximo 2,290 GBX

Mínimo 1,450 GBX

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para GlaxoSmithKline PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

12 ratings

2

Comprar

8

Manter

2

Vender

Sentimento

By Acuity

139 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.